BBA
TVRD

Baader Bank Aktiengesellschaft’s Tvardi Therapeutics TVRD Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-357
Closed -$2.7K – 550
2024
Q2 		$2.7K Buy
+357
New +$8.52K ﹤0.01% 417
2024
Q1 		– Sell
-483
Closed -$9.58K – 412
2023
Q4 		$9.58K Buy
+483
New +$20K ﹤0.01% 306

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baader Bank Aktiengesellschaft's TVRD Position: Q3 2024 in Review

Baader Bank Aktiengesellschaft sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 357 shares — an estimated $2.7K sold.

Baader Bank Aktiengesellschaft first reported a position in TVRD in Q4 2023 and held it in 2 quarters. The position peaked at $9.58K in Q4 2023. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

  • Baader Bank Aktiengesellschaft reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 357 Tvardi Therapeutics shares in Q3 2024, an estimated $2.7K.
  • Baader Bank Aktiengesellschaft first reported a position in Tvardi Therapeutics in Q4 2023 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's Tvardi Therapeutics position peaked at $9.58K in Q4 2023.
  • 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q3 2024, filed 29 Oct 2024.